

Intracameral voriconazole injection in the treatment of fungal endophthalmitis developed from keratitis

Submission date 13/12/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 06/01/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 06/01/2010	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ying-Cheng Shen

Contact details
No. 160, Sec 3
Taichung Port Rd
Taichung
Taiwan
403

Additional identifiers

Protocol serial number
YCS

Study information

Scientific Title
Intracameral voriconazole injection in the treatment of fungal endophthalmitis developed from keratitis: a retrospective non-randomised non-controlled study

Study objectives

Intracameral voriconazole administered may effectively treat fungal endophthalmitis located at anterior chamber.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Taichung Veterans General Hospital (VGHTC) ethics board approved in 2009

Study design

Retrospective non-randomised non-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Fungal endophthalmitis developed from keratitis

Interventions

100 µg of voriconazole in 0.1 ml was injected into the anterior chamber using a 30-gauge needle attached to a 1.0 ml regular insulin syringe. Intracameral voriconazole injection was given once a day and the treatment discontinued while the eyes showed disappearance of the endothelial plaque and resolution of the anterior chamber fungal infiltrate. Patients diagnosed with filamentous fungal keratitis progressing to endophthalmitis who had undergone treatment with intracameral voriconazole injection and were followed up for at least 4 months.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Voriconazole

Primary outcome(s)

Clinical observation, checked 1 month and 4 months after treatments

Key secondary outcome(s)

Checked 1 month and 4 months after treatments:

1. Visual acuity
2. Fungal infiltrate disappearance

Completion date

31/12/2008

Eligibility

Key inclusion criteria

1. Fungal endophthalmitis from keratitis
2. Anterior chamber shows fungal web, fungal balls or endothelial plaque
3. Culture approved
4. Aged 38 - 78 years, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Bacterial infection
2. Culture negative
3. Fungal infection from other source

Date of first enrolment

01/01/2005

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

Taiwan

Study participating centre

No. 160, Sec 3

Taichung

Taiwan

403

Sponsor information

Organisation

Taichung Veterans General Hospital (VGHTC) (Taiwan)

ROR

<https://ror.org/00e87hq62>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Taichung Veterans General Hospital (VGHTC) (Taiwan)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration